Snowball logo
logo
TEVA_logo

Teva Pharmaceutical Industries Ltd

TEVA TA
109.50-0.70  (0.64%)
Estimate
P/E
60.5
EPS
1.81
Beta
0.875
Growth
Revenue, YoY
-12.41%
Net income, YoY
-277.98%
FCF, YoY
318.18%
About the company
Ticker
TEVA
ISIN
IL0006290147
Country
Israel
Sector (GICS)
Healthcare
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Frequently asked questions

What sector does Teva Pharmaceutical Industries Ltd (TEVA) operate in?

Teva Pharmaceutical Industries Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is Teva Pharmaceutical Industries Ltd (TEVA) current stock price?

As of the latest data, Teva Pharmaceutical Industries Ltd stock price is ₪109.50, with a previous close of ₪110.20. Teva Pharmaceutical Industries Ltd lost -₪0.70 in the last trading session, representing a -0.64% loss.

What is Teva Pharmaceutical Industries Ltd (TEVA) current market capitalization?

Teva Pharmaceutical Industries Ltd market cap is approximately 127.60 billion.

What is Teva Pharmaceutical Industries Ltd (TEVA) Earnings Per Share (EPS)?

The trailing EPS is ₪1.81.

What is Teva Pharmaceutical Industries Ltd (TEVA) Price-to-Earnings (P/E) ratio?

Teva Pharmaceutical Industries Ltd current P/E ratio is 60.5.

What is Teva Pharmaceutical Industries Ltd (TEVA) EBITDA?

Teva Pharmaceutical Industries Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 1.21 billion.

Does Teva Pharmaceutical Industries Ltd (TEVA) pay dividends?

No. Teva Pharmaceutical Industries Ltd does not pay a dividend.

When is Teva Pharmaceutical Industries Ltd (TEVA) next earnings report?

Teva Pharmaceutical Industries Ltd is expected to release its next earnings report on June 30, 2026.

What is Teva Pharmaceutical Industries Ltd (TEVA) beta (volatility) score?

Teva Pharmaceutical Industries Ltd has a beta of 0.875, meaning its volatility is roughly in line with the market.